0000899243-22-028506.txt : 20220812
0000899243-22-028506.hdr.sgml : 20220812
20220812164938
ACCESSION NUMBER: 0000899243-22-028506
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220811
FILED AS OF DATE: 20220812
DATE AS OF CHANGE: 20220812
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KURIYEL RALF
CENTRAL INDEX KEY: 0001733143
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-14656
FILM NUMBER: 221160888
MAIL ADDRESS:
STREET 1: 41 SEYON ST
STREET 2: BLDG 1, STE. 100
CITY: WALTHAM
STATE: MA
ZIP: 02452
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REPLIGEN CORP
CENTRAL INDEX KEY: 0000730272
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042729386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7814499560
MAIL ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-11
0
0000730272
REPLIGEN CORP
RGEN
0001733143
KURIYEL RALF
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
WALTHAM
MA
02453
0
1
0
0
Senior VP, R&D
Common Stock
2022-08-11
4
M
0
2000
33.05
A
22110
D
Common Stock
2022-08-11
4
M
0
1354
59.52
A
23464
D
Common Stock
2022-08-11
4
M
0
646
86.10
A
24110
D
Common Stock
2022-08-11
4
S
0
800
255.20
D
23310
D
Common Stock
2022-08-11
4
S
0
4040
254.14
D
19270
D
Stock Option (Right to Buy)
33.05
2022-08-11
4
M
0
2000
0.00
A
2026-12-14
Common Stock
2000
0
D
Stock Option (Right to Buy)
59.52
2022-08-11
4
M
0
1354
0.00
A
2029-02-28
Common Stock
1354
0
D
Stock Option (Right to Buy)
86.10
2022-08-11
4
M
0
646
0.00
A
2027-02-23
Common Stock
646
400
D
$254.14 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.10 to $254.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option is fully vested and exercisable.
1,046 shares vest and become exercisable on 2/27/2023.
/s/ Kimberly Brown (Attorney in Fact)
2022-08-12